Efgartigimod Alfa – March 2026

• Brand names:
  • Vyvgart®
• Pharmaceutical Company:
  • ARGENX AUSTRALIA PTY. LTD.
• Condition/Indication: Generalised myasthenia gravis (gMG)
• Meeting Date: March 2026
• Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
• Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)